Quite possible BSR. Also, could explain how quiet they are about Lympro. Maybe they are not allowed to say or do anything until test results are final. If they are selling it then the new owner would be the one to communicate, not AMBS. My only question is the reference to spin out of the diagnostic division. I thought that would occur prior to a sale, build the value, and sell it as a nice package.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links